Navigation Links
Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced Cell Technology, Inc. (OTCBB: ACTC) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts. This development was announced by Robert Lanza, M.D., V.P. of Research and Scientific Development of Advanced Cell Technology (ACT) on Tuesday at the fifth annual meeting of the International Society for Stem Cell Research (ISSCR) in Cairns, Australia.

In August 2006, ACT published a paper in Nature Magazine documenting a technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple hESCs without destroying the embryo.

At the ISSCR meeting, Dr. Lanza definitively announced that he and his team have now reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved. Dr. Lanza noted at the meeting, "These are the first human embryonic stem cells in existence to be made without destroying an embryo."

This development comes on the heels of President Bush's veto of federal legislation which would have provided funding for embryonic stem cell research.

In an appearance yesterday on Bloomberg Television's "On the Economy," juxtaposed with the President's press conference relating to his stem cell funding veto, William M. Caldwell, IV, Chairman and CEO of ACT, commented on ACT's single cell blastomere development: "It does address the President's concern. We're very excited about this technology, and we're using it today to develop treatments for (addressing) macular degeneration."

Today Mr. Caldwell said, "The American people spoke through their representatives in Congress when federal funding legislation was passed by both houses and presented to the President. We are, of course, very disappointed with his veto yesterday. Our single cell b lastomere technology directly addresses the President's ethical concerns and is available today, unlike the science projects announced by the President yesterday. Despite the veto, and particularly in light of this new advance, we call on the National Institutes of Health to reflect the will of the American people and approve funding for research applications of our single cell blastomere technology."

A streaming video of the interview will be accessible later today on Advanced Cell's website by clicking here: http://www.advancedcell.com/media-gallery/.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, visit www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on pot ential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact

The Investor Relations Group
Investors:
James Carbonara or Joseph Kessler, 212-825-3210
or
Media:
Bill Douglass, 212-825-3210


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2018)... ... October 06, 2018 , ... The fantastic host of ... preventive medicine. The program focuses on topics and issues that affect the day-to-day ... , Physicians practice preventive medicine to keep patients healthy. The American Board of ...
(Date:10/5/2018)... ... October 05, 2018 , ... BioPlus Specialty Pharmacy ... of $12,000 from a company-matched employee giving program to provide support for those ... a partner for specialty pharmacy care for medical offices, patients, pharmaceutical companies, payers, ...
(Date:10/5/2018)... , ... October 05, 2018 , ... ... and alcohol treatment programs in Canada from Vancouver to Toronto, is proud to ... for better physician training. , “Detox and withdrawal from a substance such as ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 15, 2018 , ... LGC Maine Standards ... Number 205bf, for easier linearity and calibration verification. , The kit, in ... verification and verification of the reportable range for Albumin (ALB), Amylase (AMY), Cholesterol ...
(Date:10/16/2018)... Texas (PRWEB) , ... October ... ... (HCP), a Texas-based healthcare and clinical research networking-technology company founded by patient-survivors, ... improving quality and compliance in the clinical trial execution process, today announced ...
(Date:10/13/2018)... ... 12, 2018 , ... Convoy of Hope’s Disaster Services Team is currently in ... site set up to serve hurricane survivors with water, food, baby products, hygiene kits, ... 50 additional truckloads of supplies are in motion to Florida. , Convoy’s ...
(Date:10/11/2018)... ... October 11, 2018 , ... Cognosante, ... of J.Lodge, an industry leader in contact center monitoring and quality assurance. ... debilitating medical condition—J. Lodge supports alternative work environments and flexible schedules, providing remote ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... quite vulnerable to manipulation,” warns former U.S. Department of Homeland Security deputy assistant ... Vulnerable and How We Can Stop it. , Pointing to the ability of ...
Breaking Medicine News(10 mins):